+

WO2013048145A2 - Composition pour la prévention ou le traitement de maladies inflammatoires ou de maladies liées à la réduction de la masse osseuse, contenant du 6-(3-hydroxyphényle)-2-naphtol ou son sel pharmaceutiquement acceptable en tant que principe actif - Google Patents

Composition pour la prévention ou le traitement de maladies inflammatoires ou de maladies liées à la réduction de la masse osseuse, contenant du 6-(3-hydroxyphényle)-2-naphtol ou son sel pharmaceutiquement acceptable en tant que principe actif Download PDF

Info

Publication number
WO2013048145A2
WO2013048145A2 PCT/KR2012/007824 KR2012007824W WO2013048145A2 WO 2013048145 A2 WO2013048145 A2 WO 2013048145A2 KR 2012007824 W KR2012007824 W KR 2012007824W WO 2013048145 A2 WO2013048145 A2 WO 2013048145A2
Authority
WO
WIPO (PCT)
Prior art keywords
bone
naphthol
hydroxyphenyl
osteoporosis
diseases
Prior art date
Application number
PCT/KR2012/007824
Other languages
English (en)
Korean (ko)
Other versions
WO2013048145A3 (fr
Inventor
민도식
유현정
서홍석
강동우
박성환
Original Assignee
부산대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110099721A external-priority patent/KR20130035425A/ko
Priority claimed from KR1020120035506A external-priority patent/KR101401002B1/ko
Application filed by 부산대학교 산학협력단 filed Critical 부산대학교 산학협력단
Publication of WO2013048145A2 publication Critical patent/WO2013048145A2/fr
Publication of WO2013048145A3 publication Critical patent/WO2013048145A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention is an inflammatory disease or bone loss-related diseases comprising 6- (3-hydroxyphenyl) -2-naphthol (6- (3-Hydroxyphenyl) -2-naphthol) or a pharmaceutically acceptable salt thereof as an active ingredient It relates to a composition for the prophylaxis or treatment of.
  • Inflammation is one of tissue damage, an external stimulus, or a defense response of biological tissues to various infectious agents. Inflammation is the activation of enzymes, inflammatory mediators, and cell infiltration due to organic interactions between various inflammatory mediators and various immune cells in blood vessels and body fluids. A series of complex pathologies, including fluid exudation, circulatory disorders, tissue degeneration and hyperproliferation. Inflammatory reactions occur in the early stages when macrophages gather into the wound and attack the invading bacteria, then plasma builds up in the wound and increases blood flow resulting in external symptoms such as fever, erythema, swelling and pain. . If these inflammatory reactions occur continuously or excessively, they proceed to the main pathology of the disease (sensitized allergic disease, chronic inflammatory disease), which leads to serious abnormal disorders.
  • Macrophage is a multifunctional cell that plays an important role in the inflammatory response by generating various cytokines and nitric oxides (NO) by chemical stimulation.
  • Inducible nitric acidase especially expressed by cytokine stimulation such as lipopolysaccharide (LPS), interferon- ⁇ , and tumor necrosis factor- ⁇ (TNF- ⁇ ) in macrophages oxide synthase (iNOS) produces large amounts of NO over long periods of time.
  • LPS lipopolysaccharide
  • TNF- ⁇ tumor necrosis factor- ⁇
  • iNOS macrophages oxide synthase
  • Activated NF ⁇ B is known to migrate to the nucleus and promote gene expression that induces several inflammatory responses, such as iNOS, COX-2 and interleukin-1 ⁇ , IL-1 ⁇ , or TNF- ⁇ . Inhibition of factors is known to inhibit inflammatory responses (Baeuerle et al., Annu. Rev. Immunol., 12: 141-179, 1994). Therefore, the search for a substance that inhibits the production of TNF- ⁇ , NO, prostaglandin or IL-1 ⁇ may prove to be an effective substance for inflammatory diseases such as edema or dermatitis.
  • NSAID S non-steroidal anti-inflammatory drug
  • COX cyclooxygenase
  • the bone repeats the cycle for about 120 to 150 days, including bone resorption by osteoclasts, bone formation and osteostasis by osteoblasts.
  • bone resorption and bone formation are precisely regulated, resulting in little change in overall bone mass.
  • the balance of both is broken, resulting in a decrease in bone mass and deterioration of bone tissue. Because of this, fractures occur easily, which causes the disease to lie down, deformation of the body, and death depending on the fracture site.
  • Osteoporosis is a systemic disease whose main symptoms are a decrease in bone mass and deterioration of bone tissue. Osteoporosis is a condition in which bone mineralization is reduced by thinning the bone tissue and the bone marrow cavity is widened. As a result, the bone weakens as the symptoms progress, so it is easy to fracture even in a small impact. Bone mass is influenced by many factors, including genetic factors, nutrition, hormone changes, differences in exercise and lifestyle, and the causes of osteoporosis include old age, lack of exercise, low weight, smoking, low calcium diet, menopause, Ovarian ablation and the like are known.
  • bone mass is highest at 14-18 years of age and decreases by about 1% per year in old age. Especially in women, bone reduction continues after 30 years of age, and when menopause reaches bone growth rapidly due to hormonal changes.
  • osteoporosis is unavoidable for the elderly, especially postmenopausal women, and as the population ages in developed countries, interest in osteoporosis and its therapeutics is gradually increasing. It is also known that there is a market of about $ 130 billion related to the treatment of bone diseases around the world, and it is expected to increase further, so that various research institutes and pharmaceutical companies around the world are investing in the development of the treatment for bone diseases. .
  • the treatment of osteoporosis includes general therapies and pharmacotherapy.
  • General therapies require changes in calcium and vitamin D intake, exercise and lifestyle changes.
  • Medications include hormonal supplementation, alendronate, calcitonin, raloxifene, Na-F, calcitriol, and bisphosphonate preparations.
  • Osteoporosis treatment requires a long-term treatment period, it is necessary to develop a new osteoporosis treatment agent that does not have side effects due to side effects such as urolithiasis, endometrial cancer, breast cancer when long-term administration of conventional drugs.
  • osteoporosis Materials currently used to treat osteoporosis include estrogens, androgen anabolic steroids, calcium preparations, phosphates, fluorides, ifriflavones, and vitamin D3.
  • Merck, USA developed aminobisphosphonate
  • raloxifene which acts as a selective estrogen receptor regulator, was developed as a new drug for osteoporosis.
  • Conventional osteoporosis therapeutic agents are mostly estrogen-based substances, and estrogen-based substances are known to exhibit side effects such as cancer, gallstones, and thrombosis when administered for a long time.
  • osteoporosis cannot be treated with short-term administration of drugs, and long-term administration of drugs is essential. Therefore, long-term administration of drugs does not have such side effects, and there is an urgent need for the development of new substances with superior efficacy to replace estrogen. Situation.
  • the present inventors have endeavored to develop a composition for preventing or treating inflammatory diseases or bone loss-related diseases without toxicity and side effects, resulting in 6- (3-hydroxyphenyl) -2-naphthol (6- (3-Hydroxyphenyl).
  • 6- (3-hydroxyphenyl) -2-naphthol 6- (3-Hydroxyphenyl).
  • the present invention was completed by confirming that) -2-naphthol) showed an excellent inflammatory disease or a prophylactic or therapeutic effect of a disease related to bone loss.
  • An object of the present invention to provide a pharmaceutical composition for the prevention or treatment of inflammatory diseases or bone loss-related diseases comprising 6- (3-hydroxyphenyl) -2-naphthol or a pharmaceutically acceptable salt thereof as an active ingredient. will be.
  • Another object of the present invention to provide a food composition for the prevention or improvement of inflammatory diseases or bone loss-related diseases comprising 6- (3-hydroxyphenyl) -2-naphthol or a pharmaceutically acceptable salt thereof as an active ingredient. It is.
  • the present invention is to prevent or treat inflammatory diseases or bone loss-related diseases comprising 6- (3-hydroxyphenyl) -2-naphthol or a pharmaceutically acceptable salt thereof as an active ingredient It provides a pharmaceutical composition.
  • the present invention also provides a food composition for the prevention or improvement of inflammatory diseases or bone loss-related diseases comprising 6- (3-hydroxyphenyl) -2-naphthol or a pharmaceutically acceptable salt thereof as an active ingredient.
  • 6- (3-hydroxyphenyl) -2-naphthol of the present invention inhibits the production of proinflammatory cytokines in synovial cells, reduces the incidence of arthritis and clinical disease index of arthritis in arthritis animal models, It has an excellent effect of suppressing loss and deformation, reducing the degree of inflammation of the synovial tissue, the degree of bone erosion, the degree of cartilage cell destruction and the infiltration of immune cells, and thus can be used as a composition for preventing or treating inflammatory diseases including arthritis. have.
  • the 6- (3-hydroxyphenyl) -2-naphthol of the present invention inhibits the formation of osteoclasts, decreases bone resorption, inhibits bone loss and ovarian extraction in LPS-induced bone resorption animal models
  • the animal model has an excellent effect of improving the striatal bone mass, striatal bone thickness, striatal bone marrow, aerospace space, etc., can be used as a composition for the prevention or treatment of diseases related to bone loss, including osteoporosis.
  • IL-6 pro-inflammatory cytokines
  • IL-8 pro-inflammatory cytokines
  • Figure 2 shows the amount of pro-inflammatory cytokines (IL-6, IL-8, MCP-1) after treatment with TNF- ⁇ and 6- (3-hydroxyphenyl) -2-naphthol in synovial cells. to be.
  • FIG. 3 is a diagram showing the incidence of arthritis according to administration of 6- (3-hydroxyphenyl) -2-naphthol in the collagen-induced arthritis mouse model.
  • FIGS. 4 and 5 are diagrams showing the effect of treating foot edema following administration of 6- (3-hydroxyphenyl) -2-naphthol in the collagen-induced arthritis mouse model as an arthritis clinical disease index.
  • FIG. 6 is a diagram illustrating three-dimensional reconstruction of knee joint and hind paw tissue of the collagen-induced arthritis mouse model through micro-computed tomography.
  • FIG. 7 is a diagram showing the knee cross section of the collagen-induced arthritis mouse model through trichrome and safranin-O staining.
  • FIG. 8 is a diagram showing the degree of inflammation of the knee tissue (the degree of inflammation of the synovial tissue, the degree of bone erosion, the degree of chondrocyte destruction and immune cell infiltration) of the collagen-induced arthritis mouse model.
  • FIG. 9 is a diagram showing the concentration of inflammatory cytokines (TNF- ⁇ , IL-1 ⁇ , IL-6, INF- ⁇ , MCP-1 and IL-17) in the serum of the collagen-induced arthritis mouse model.
  • FIG. 10 is treated with 6- (3-hydroxyphenyl) -2-naphthol with concentrations of osteoclasts (M-CSF and RANKL) in macrophages obtained from mouse bone marrow and cultured for 9 days. The number of osteoclasts is shown through TRAP staining.
  • FIG. 11 is treated with 6- (3-hydroxyphenyl) -2-naphthol with concentrations of osteoclasts (M-CSF and RANKL) in macrophages obtained from mouse bone marrow and cultured for 9 days.
  • Figure shows the degree of differentiation into (A: osteoclast number, B: quantification by measuring TRAP activity).
  • FIG. 12 shows hydroxyapatite for 9 days by treating 6- (3-hydroxyphenyl) -2-naphthol with concentrations of osteoclasts (M-CSF and RANKL) in macrophages obtained from mouse bone marrow. After culturing in a well coated plate, the bone absorbed area is shown (A: micrograph, B: pit area, C: number of absorbed feet).
  • Figure 13 is a macrophage obtained from the mouse bone marrow treated with osteoclasts differentiator (M-CSF and RANKL) with 6- (3-hydroxyphenyl) -2-naphthol concentrations in the cells obtained after 9 days incubation
  • M-CSF and RANKL osteoclasts differentiator
  • 6- (3-hydroxyphenyl) -2-naphthol concentrations in the cells obtained after 9 days incubation
  • It is a diagram showing the mRNA expression of osteoclast target genes (A: TRAP, B: calcitonin receptor, C: cathepsin K related mRNA expression).
  • FIG. 14 is a three-dimensional image of a skull obtained after daily injection of 6- (3-hydroxyphenyl) -2-naphthol at 10 mg / kg for 6 days in an LPS-induced bone resorption animal model. Reconstructed diagram.
  • FIG. 15 is a photograph (A) of TRAP staining of a cross section of a skull obtained after daily injection of 6- (3-hydroxyphenyl) -2-naphthol at 10 mg / kg for 6 days in an LPS-induced bone resorption animal model; The graph (B) which quantified the osteoclast staining site area is shown.
  • FIG. 16 is a graph illustrating bone analysis of the femur obtained after 24 injections of 6- (3-hydroxyphenyl) -2-naphthol at 10 mg / kg into the abdominal cavity at 2 days intervals in an ovarian isolated animal model (A A: holding bone mass, B: holding bone thickness, C: holding bone marrow, D: holding space area.
  • the present invention provides a composition for the prevention and treatment of inflammatory diseases or bone loss-related diseases comprising 6- (3-hydroxyphenyl) -2-naphthol or a pharmaceutically acceptable salt thereof as an active ingredient represented by the following formula (1) to provide.
  • the composition comprises a pharmaceutical composition or a food composition.
  • 6- (3-hydroxyphenyl) -2-naphthol of Chemical Formula 1 is a resveratrol derivative having a molecular formula of C 16 H 2 O 2 and a molecular weight of 236.0837.
  • resveratrol is a natural substance present in herbs, grape skins, nuts and red wine.
  • Pharmaceutically acceptable salts of 6- (3-hydroxyphenyl) -2-naphthol in the present invention include all salts of acidic or basic groups which may be present in the compounds of the structure shown in formula (I). Examples include the sodium, calcium and potassium salts of the hydroxy group and include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandel Latex, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate), and the like, but are not limited thereto as long as they can be prepared through a method or a process for preparing a salt known in the art.
  • 6- (3-hydroxyphenyl) -2-naphthol of the present invention inhibits the production of proinflammatory cytokines in synovial cells, reduces the incidence of arthritis and clinical disease index of arthritis in arthritis animal models, It has an excellent effect of suppressing loss and deformation, relieving synovial tissue inflammation, bone erosion, cartilage destruction and immune cell infiltration.
  • the 6- (3-hydroxyphenyl) -2-naphthol of the present invention inhibits the formation of osteoclasts, decreases bone resorption, inhibits bone loss and ovarian extraction in LPS-induced bone resorption animal models In animal model, it has excellent effect to improve strut bone mass, strut bone thickness, strut bone marrow, and strut space area.
  • 6- (3-hydroxyphenyl) -2-naphthol according to the present invention has an excellent therapeutic effect against inflammatory diseases or bone loss-related diseases, it is useful for the prevention or treatment of inflammatory diseases or bone loss-related diseases. It can be used as a useful medicine or dietary supplement.
  • inflammatory disease is a dermatitis, allergy, atopic, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus , Fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, periarthritis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, acute inflammation and chronic inflammation, Preferably osteoarthritis or rheumatoid arthritis, most preferably rheumatoid arthritis.
  • the "bone loss-related disease” refers to a disease in which bone loss occurs with symptoms such as a decrease in bone density and deterioration of bone tissue.
  • primary osteoporosis eg, primary osteoporosis with age, primary osteoporosis with menopause, primary osteoporosis with ovarian extraction, etc.
  • secondary osteoporosis eg, glucocorticoid-induced osteoporosis, thyroid function
  • 3) cancer metastasis hypercalcemia
  • Bone diseases such as jet disease, bone defects (alveolar bone defects, mandibular bone defects, childhood sudden bone defects, etc.), bone necrosis, etc.
  • composition of the present invention may further contain at least one known active ingredient having 6- (3-hydroxyphenyl) -2-naphthol and a prophylactic or therapeutic effect for inflammatory diseases or bone loss-related diseases.
  • composition of the present invention may further include a component that does not increase the efficacy, but may improve the odor, taste, time, etc. that are commonly used in pharmaceutical compositions.
  • composition of the present invention is an inorganic or organic additive such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. These may further include.
  • composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions. It may also be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like in the form of conventional formulations, external preparations, suppositories, and sterile injectable solutions. Suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceutical Science, recently, Mack Publishing Company, Easton PA.
  • Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose , Microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations are prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like in the composition. It is prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be used. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvents and suspending agents may be used propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like.
  • injectable esters such as ethyl oleate and the like.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • 6- (3-hydroxyphenyl) -2-naphthol of the present invention may be included in 0.001 to 50% by weight, preferably 0.01 to 20% by weight in the total pharmaceutical composition.
  • the 6- (3-hydroxyphenyl) -2-naphthol can be adjusted in an amount such that an appropriate amount can be administered per kg of the individual to which the pharmaceutical composition is administered.
  • the 6- (3-hydroxyphenyl) -2-naphthol when the individual to which the 6- (3-hydroxyphenyl) -2-naphthol is administered is a human, the 6- (3-hydroxyphenyl) -2-naphthol is 0.0001 to 500 mg / kg, preferably The content included in the pharmaceutical composition may be adjusted to be administered in an amount of 0.001 to 500 mg / kg, more preferably 0.001 to 300 mg / kg.
  • composition of the present invention can be administered to a subject to prevent or treat inflammatory diseases or diseases related to bone loss.
  • “individual” refers to a mammal, such as horses, sheep, pigs, goats, dogs, etc., including a human having a disease that can improve symptoms by administering the pharmaceutical composition of the present invention.
  • administration in the present invention is meant to provide the subject with the composition of the present invention in any suitable way. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the sex, age, severity, drug activity, drug of the patient. Sensitivity to, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses.
  • compositions of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention or treatment of inflammatory diseases or bone loss associated diseases.
  • 6- (3-hydroxyphenyl) -2-naphthol of the present invention may be added to a dietary supplement for the purpose of preventing or ameliorating inflammatory diseases or diseases related to bone loss.
  • Food of the present invention can be used in the form of capsules, tablets, powders, liquid suspensions, pills and granules, but is not limited thereto.
  • the dietary supplement in tablet form may be prepared as it is or by adding excipients, binders, disintegrants or other additives into granules in a suitable manner and then compressed and molded by adding a lubricant or the like.
  • excipients, binders, disintegrants or other suitable additives Either by direct compression molding of an even mixture of excipients, binders, disintegrants or other suitable additives, or by mixing the nutraceuticals as they are or by adding the appropriate additives and mixing them evenly and then compression molding or excipients in the nutraceuticals, A binder or other suitable additive is added to evenly mix the powder with a solvent, the wet powder is molded into a mold at low pressure, and then dried and prepared by a suitable method.
  • the nutraceutical can be added to the health functional food in the form of tablets, if necessary, can be avoided with a suitable epidermis.
  • the hard capsules are usually a mixture of a dietary supplement or an excipient suitable for a dietary supplement, or granulated by a suitable method, or granulated by a suitable epidermal, as it is or Soft capsules are prepared by filling them, and soft capsules are usually packed in capsules containing glycerin or sorbitol in a suitable capsule base such as gelatin, with appropriate excipients for health functional food or health functional food. It is prepared by molding into a shape, and if necessary, a coloring preservative or the like may be added to the capsule base.
  • Supplements, binders, disintegrants, etc. are usually mixed into a dietary supplement and then molded into a spherical form by appropriate methods. You can also be greeted with a suitable substance.
  • Functional foods in granule formulations are usually made by adding functional foods or excipients, binders, disintegrants, etc., and mixing them evenly and then granulating them in a proper way to make the particles as even as possible. , Mating agent, etc. can be added.
  • the nutraceuticals of the beverage formulations may contain various flavors or natural carbohydrates, etc. as additional ingredients, like conventional beverages.
  • natural carbohydrates are sugars such as glucose, monosaccharides such as fructose, maltose, disaccharides such as sucrose, dextrins, polysaccharides such as cyclodextrins, xylitol, sorbitol, and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • Functional ingredients such as deer antler extract, fructooligosaccharide, acacia honey, which help to absorb bowel movements and calcium absorption, complex golden extract, which is a natural preservative, and gellan gum, which are sediment improving agents, can be added, but are not limited thereto. Suitable components can be used as appropriate.
  • the proportion of the natural carbohydrate is generally about 0.001 to 0.4 g, preferably about 0.002 to 0.03 g per 100 ml of the food composition of the present invention.
  • the composition of the present invention When the composition of the present invention is used as a food additive, the composition may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). Generally, in the preparation of food or beverages the compositions of the invention are added in amounts of up to 15% by weight, preferably up to 10% by weight relative to the raw materials. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, it may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
  • 6- (3-hydroxyphenyl) -2-naphthol is a resveratrol derivative having the molecular formula C 16 H 2 O 2 and a molecular weight of 236.0837.
  • 6- (3-hydroxyphenyl) -2-naphthol was quantified using an electronic balance, dissolved in DMSO, and diluted in sterile PBS to 10% DMSO. Prepared.
  • TNF- was obtained after culturing and culturing fibroblast-like synoviocytes obtained from surgery in arthritis patients. Stimulation with ⁇ increased the production of proinflammatory cytokine, followed by treatment with 6- (3-hydroxyphenyl) -2-naphthol. Thereafter, mRNA changes of each proinflammatory cytokine were confirmed by reverse transcriptase PCR, and the production amount of each proinflammatory cytokine was confirmed by ELISA. The results are shown in FIGS. 1 and 2, respectively.
  • the mRNA and the amount of proinflammatory cytokines such as IL-6, IL-8 and MCP-1 were produced by treatment with 6- (3-hydroxyphenyl) -2-naphthol. It was confirmed that the decrease.
  • bovine type 2 collagen was homogeneously emulsified using a T-connector connected to a 3 ml syringe while cooling with Freund's adjuvant on ice.
  • the emulsified bovine type 2 collagen solution was injected intradermally into the tail tip of 6-week-old DBA1 / J mice to administer the immunogen.
  • the emulsified bovine type 2 collagen solution was injected intradermally into the tail of the mouse to induce a secondary immune response. Symptoms of arthritis gradually after secondary immunity.
  • the 6- (3-hydroxyphenyl) -2-naphthol injection prepared in Example was injected into the abdominal cavity of mice at a total of 12 injections for 3 weeks at a time of 2 days at 5 mg / kg. It was.
  • the control vehicle was injected intraperitoneally with 10% DMSO only.
  • 6- (3-hydroxyphenyl) -2-naphthol showed no toxic signal and no lethality of mice was observed.
  • the clinical arthritic score index of the arthritis of the mice was checked during the experiment.
  • the clinical disease index of arthritis was scored as follows.
  • the best score for the joint lesion was 4 per leg, and the best score was 16 for the left and right forefoot and hind foot per mouse.
  • the control group showed typical arthritis findings of cartilage and bone loss and deformation in the knee joint and hind paw, and the 6- (3-hydroxyphenyl) -2-naphthol group of the present invention was normal mice. Similar findings were observed, confirming the excellent therapeutic effect for arthritis.
  • Knee tissues of the mouse were separated, fixed in 10% NBF (neutral buffered formalin) solution, and subjected to calcium decalcification (decalcification) using 10% EDTA solution, and then embedded in paraffin. After 4 ⁇ m tissue sections were made, trichrome staining for bone staining and safranin-O staining for cartilage staining were performed. In addition, researchers trained using the tissue staining photographs may not know which animals have been given a vehicle or drug, and thus the incidence and severity of arthritis may be associated with synovial inflammation and bone erosion. ), Four factors including cartilage damage and leukocyte infiltration were determined according to the evaluation criteria of 0 to 4. The results are shown in FIGS. 7 and 8, respectively.
  • the concentration of inflammatory cytokines (TNF- ⁇ , IL-1 ⁇ , IL-6, INF- ⁇ , MCP-1, and IL-17) in mouse blood was measured using ELISA. The results are shown in FIG.
  • 6- (3-hydroxyphenyl) -2-naphthol of the present invention is very excellent in preventing and treating arthritis.
  • Muscle tissue around the leg bone (femur, tibia) of the 6-8 week old Balb / c mouse was removed cleanly, cut at both ends of the femur, plugged with a syringe needle, and washed down with medium until the bone marrow completely drained. Bone marrow was collected and centrifuged at 2000 rpm for 5 minutes to obtain cells. The cells were resuspended in alpha-MEM medium containing 10% FBS, aliquoted into a culture dish, and then in a 37 ° C. and 5% CO 2 incubator. Incubated.
  • non-attached cells were collected and centrifuged at 2000 rpm for 5 minutes to collect the cells, which were incubated for 3 days in alpha-MM medium containing M-CSF (50 ng / ml) and 10% FBS for macrophages. Differentiated to After 3 days, the adherent cells were collected and cultured in alpha-M medium containing M-CSF (50 ng / ml), RANKL (50 ng / ml) and 10% FBS to induce differentiation into osteoclasts.
  • the macrophages obtained in Experimental Example 3-1 were inoculated into a well plate (Biologic, BD) coated with hydroxyapatite (hydroxyapatite), and then 6- (3-hydroxyphenyl) -2-naphthol was inoculated. Concentration (0, 5, 10 ⁇ M) was added to the wells and incubated for 9 days. The area of the pit formed on the hydroxyapatite slide was measured. The results are shown in FIG.
  • the expression of TRAP-related mRNA was about 4-5 fold and the expression of calcitonin receptor-related mRNA was about 2-3 by treatment with 6- (3-hydroxyphenyl) -2-naphthol of the present invention. It was confirmed that the expression of embryo, cathepsin K-related mRNA was inhibited about five-fold, through which the expression of osteoclast differentiation-related genes was greatly reduced.
  • the skull of the mouse was isolated and fixed in 10% neutral buffered formalin (NBF) fixative, and then decalcified using 10% EDTA solution and embedded in paraffin. Thereafter, tissue sections of 4 ⁇ m were made and TRAP staining was performed. The results are shown in FIG.
  • the 6- (3-hydroxyphenyl) -2-naphthol-administered group of the present invention was found to have about 2 to 3 times more bone area than the control group administered with LPS only. .
  • 6- (3-hydroxyphenyl) -2-naphthol (10 mg / kg) was intraperitoneally injected 24 times for 8 weeks at a time interval of 2 days.
  • PBS was administered to the normal group (sham) without ovarian extraction and the control group (OVX) with ovarian extraction.
  • mice The femurs of the mice were separated and bone analyzes were performed (abutment bone mass (BT / TV (%), striatal bone thickness (Tb.Th), striatal bone marrow (Tb.Sp), strut space area measurement (Tb.N)). The results are shown in FIG.
  • the 6- (3-hydroxyphenyl) -2-naphthol-administered group of the present invention compared to the control group (OVX) to which only PBS was administered, 4 of the strut bone mass, strut bone thickness, strut bone marrow, and strut space area. It was confirmed that about 20% to 60% of all the indicators were effective in treating osteoporosis.
  • 6- (3-hydroxyphenyl) -2-naphthol of the present invention is very excellent in inhibiting the occurrence or treatment effect of bone loss-related diseases.
  • the above ingredients are mixed and filled in an airtight cloth to prepare a powder.
  • tablets are prepared by tableting according to a conventional method for preparing tablets.
  • the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
  • the amount of the above ingredient is prepared per ampoule (2 ml).
  • Vitamin B6 0.5 mg
  • composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • the resulting solution is filtered and obtained in a sterilized 2 l container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.
  • composition ratio is a composition suitable for a preferred beverage in a preferred embodiment
  • the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
  • 6- (3-hydroxyphenyl) -2-naphthol of the present invention inhibits the production of proinflammatory cytokines in synovial cells, reduces the incidence of arthritis and clinical disease index of arthritis in arthritis animal models, It has an excellent effect of suppressing loss and deformation, reducing the degree of inflammation of the synovial tissue, the degree of bone erosion, the degree of cartilage cell destruction and the infiltration of immune cells, and thus can be used as a composition for preventing or treating inflammatory diseases including arthritis. have.
  • the 6- (3-hydroxyphenyl) -2-naphthol of the present invention inhibits the formation of osteoclasts, decreases bone resorption, inhibits bone loss and ovarian extraction in LPS-induced bone resorption animal models
  • the animal model has an excellent effect of improving the striatal bone mass, striatal bone thickness, striatal bone marrow, aerospace space, etc., can be used as a composition for the prevention or treatment of diseases related to bone loss, including osteoporosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pour la prévention ou le traitement de maladies inflammatoires ou de maladies liées à la réduction de la masse osseuse, contenant du 6-(3-hydroxyphényle)-2-naphtol ou son sel pharmaceutiquement acceptable en tant que principe actif. Le 6-(3-hydroxyphényle)-2-naphtol de la présente invention empêche la production de cytokine pro-inflammatoire dans les cellules synoviales, réduit le taux de progression de l'arthrite et l'indice de maladie clinique de l'arthrite dans un modèle animal atteint d'arthrite, supprime la perte et la déformation du cartilage et des os, et soulage le degré d'inflammation du tissu synovial, l'ampleur de l'érosion osseuse et de la destruction des chondrocytes, et l'infiltration des immunocytes. Ainsi, il peut être utilisé en tant que composition dans la prévention ou le traitement de maladies inflammatoires incluant l'arthrite. En outre, le 6-(3-hydroxyphényle)-2-naphtol de la présente invention inhibe la formation d'ostéoclastes, réduit la résorption osseuse, supprime la perte osseuse chez un modèle animal présentant une résorption osseuse induite par les lipopolysaccharides, et améliore le volume, l'épaisseur et le nombre d'os trabéculaires, ainsi que l'espace trabéculaire et analogue dans un modèle animal ovariectomisé. Ainsi, il peut être utilisé en tant que composition dans la prévention ou le traitement de maladies liées à la réduction de la masse osseuse, incluant l'ostéoporose.
PCT/KR2012/007824 2011-09-30 2012-09-27 Composition pour la prévention ou le traitement de maladies inflammatoires ou de maladies liées à la réduction de la masse osseuse, contenant du 6-(3-hydroxyphényle)-2-naphtol ou son sel pharmaceutiquement acceptable en tant que principe actif WO2013048145A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0099721 2011-09-30
KR1020110099721A KR20130035425A (ko) 2011-09-30 2011-09-30 Ｈｓ1792를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물
KR10-2012-0035506 2012-04-05
KR1020120035506A KR101401002B1 (ko) 2012-04-05 2012-04-05 Ｈｓ1792 또는 이의 약학적으로 허용되는 염을 포함하는 골량 저하 관련 질환의 예방 또는 치료용 약학 조성물 및 건강기능식품

Publications (2)

Publication Number Publication Date
WO2013048145A2 true WO2013048145A2 (fr) 2013-04-04
WO2013048145A3 WO2013048145A3 (fr) 2013-07-04

Family

ID=47996629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007824 WO2013048145A2 (fr) 2011-09-30 2012-09-27 Composition pour la prévention ou le traitement de maladies inflammatoires ou de maladies liées à la réduction de la masse osseuse, contenant du 6-(3-hydroxyphényle)-2-naphtol ou son sel pharmaceutiquement acceptable en tant que principe actif

Country Status (1)

Country Link
WO (1) WO2013048145A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037171A1 (fr) * 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoïdes inhibiteurs d'il-17a

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037171A1 (fr) * 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoïdes inhibiteurs d'il-17a
US20160068502A1 (en) * 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoid il-17a inhibitors
US10385034B2 (en) 2014-09-05 2019-08-20 The Cleveland Clinic Foundation Flavonoid IL-17A inhibitors

Also Published As

Publication number Publication date
WO2013048145A3 (fr) 2013-07-04

Similar Documents

Publication Publication Date Title
WO2018194309A1 (fr) Composition pharmaceutique contenant de l'indirubine en tant que substance active
JP2014507374A (ja) 金銀花抽出物を含む逆流性食道炎治療または予防用薬学組成物
WO2022050516A1 (fr) Agent thérapeutique contre le coronavirus comprenant un extrait d'elaeocarpus sylvestris en tant que principe actif
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2020166779A1 (fr) Composition pour l'inhibition de la formation de graisse et la réduction de la graisse corporelle, contenant de l'hydrangénol en tant que principe actif
CN119235936A (zh) 包含使君子提取物的用于预防或治疗前列腺增生的组合物
WO2012008788A2 (fr) Composition contenant de la sérine en tant que principe actif pour la prévention et le traitement de stéatoses hépatiques, et utilisation de celle-ci
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
WO2017073849A1 (fr) Composition pour la prévention ou le traitement de l'arthrite, contenant un extrait de sargassum serratifolium en tant que substance active
WO2020040432A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies musculaires, contenant un extrait de baie de ginseng en tant que principe actif
WO2017082478A1 (fr) Composition pharmaceutique visant à prévenir ou traiter l'ostéoporose et contenant un extrait de germe de soja
KR101752697B1 (ko) 나프토퀴논계 화합물을 유효성분으로 포함하는 췌장염 예방 및 치료용 조성물
WO2012134172A2 (fr) Composition contenant, comme ingrédient actif, une fraction d'acétate d'éthyle de schisandra chinensis baill, ou wuweizisu c séparée de la fraction, pour prévenir ou traiter l'obésité
WO2016010340A1 (fr) Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation
KR101964054B1 (ko) 금은화 추출물을 포함하는 크론병 치료 또는 예방용 약학조성물
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
WO2022270760A1 (fr) Méthode de traitement de la stéatohépatite non alcoolique par la co-administration d'un dérivé de la curcumine et d'un inhibiteur du récepteur de tgf-β
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée
WO2013048145A2 (fr) Composition pour la prévention ou le traitement de maladies inflammatoires ou de maladies liées à la réduction de la masse osseuse, contenant du 6-(3-hydroxyphényle)-2-naphtol ou son sel pharmaceutiquement acceptable en tant que principe actif
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
CN108697723A (zh) 鬼针草对增加肌肉和减少脂肪的有益效果
KR101445966B1 (ko) 백두구 추출물을 포함하는 항비만 조성물
WO2018208107A1 (fr) Composition pour atténuer, prévenir ou traiter un trouble du sommeil ou composition pour supprimer la résistance à un agoniste du site de liaison aux benzodiazépines du récepteur gaba-a, ou pour atténuer un effet secondaire d'un agoniste du site de liaison aux benzodiazépines du récepteur gaba-a, chaque composition comprenant du phloroglucinol en tant que principe actif
KR101851639B1 (ko) 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물
WO2017030419A1 (fr) Composition incluant un extrait ou une fraction raf. d'euphorbia supina comme ingrédient actif pour la prévention ou le traitement de l'obésité

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 12835578

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载